Parcor

Sanofi

Sanofi Sa

Sanofi-synthelabo

Sanofi-aventis

Elf Sanofi

Asterol International

Pacor

Monserbio

Jean-Pierre Maffrand

Daniel Frehel

Alain Badorc

Paul De Cointet

Pierre Despeyroux

Eric Vallee

Jean-Marie Pereillo

Robert Boigegrain

Danielle Gully

Jean-Marc Herbert

Armand Amselem

Gerard Ferrand

Andre Bernat

Daniele Anne Gully

Fernand Eloy

Shinichiro Ashida

Norio Suzuki

Jean Courregelongue

Pierre Casellas

Bernard Bourrie

Pierre M Roger

Francoise Bono

Nathalie Guillo

Pierre Savi

Michel Jacques Geslin

Gilles Anne-Archard

Alain Bayol

Françoise Bono

Pierre Fons

Jean-Pierre Bras

Jacqueline Lansen

Alain Heymes

Daniel Aubert

Francis Blanc

Eric Bignon

Rebecca Pruss

Denis Delebass Ee

Andr E Bernat

Marie-Francedillaoise Bordes

Alan Heymes

Denis Delabassee

Michel Gachon

Gerard Maire

Kynichi Matsubayashi

Claude Ferrand

Kynichi Matsubayachi

Denis Delebassee

Jacob-Alsboek Olsen

Chantal Guenet

Corinne Heckel

Ghislain Defreyn

Gilles Kieffer

FGF receptor agonist compounds corresponding to the general formula: M1-L-M2 are disclosed in which M1 and M2, which may be identical or different, each represent, independently of one another, a monomer unit M, and L represents a linker group, wherein the monomer unit is of the general formula I. 

FGF-receptor agonist dimeric compounds

The invention concerns a compound of general formula (I), wherein: X represents an oxygen or sulphur atom; Rrepresents, independently of each other when n=2 or 3, a halogen atom, a hydroxy, a C-Calkyl, a C-Calkoxy, a trifluoromethyl, a trifluoromethyloxy or a methylenedioxy; Rrepresents a C-Calkyl group optionally substituted, a C-Ccycloalkyl, piperidinyl or phenyl group, the C-Ccycloalkyl, piperidinyl or phenyl groups being optionally substituted; Rrepresents a hydrogen atom or a C-Calkyl group optionally substituted; Rrepresents a hydrogen atom or a C-C4 alkyl group; and Rand Rrepresent, independently of each other, a hydrogen atom, a hydroxy, a halogen atom, a C-Calkyl group, or Rand Rform together an oxo group; Rrepresents a hydrogen atom, a halogen atom, a C-Calkyl, a C-Calkoxy, a trifluoromethyl, or a trifluoromethoxy; in the form of a base, addition to an acid, hydrate or solvate. The invention is applicable in therapy 

Acylaminothiazole derivatives, their preparation and therapeutic use

The present invention relates to novel branched substituted amino derivatives of 3-amino-1-phenyl-1H-&lsqb;1,2,4&rsqb;triazole, processes for their preparation and pharmaceutical compositions comprising them.

Branched substituted amino derivatives of 3-amino-1-phenyl-1h-&lsqb;1,2,4&rsqb;triazol, methods for producing them and pharmaceutical compositions containing them

Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination

The invention relates to the compounds of formula (I) ##STR1## in which R.sub.I, R.sub.II, X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are as defined in claim 1.

Polysubstituted 3-acylamino-5-phenyl-1,4-benzodiazepin-2-one

The present invention relates to compounds of formula: ##STR1## which are agonists of cholecystokinin receptors and pharmaceutical compositions containing them.

Glycinamide derivatives, processes for their preparation and medicines

Polysubstituted 3-acylamino-5-phenyl-1, 4-benzodiazepin-2-one

The invention concerns compounds of formula ##STR1## in which R, A, R.sub.1 and Y are as defined in claim 1. The instant compounds have an affinity for the fibrinogen receptor: the complex of the glycoproteins IIb/llIa (GP IIb/IIIa); more particularly, the subject of the present invention is new inhibitors of platelet aggregation which are antagonists of the GP IIb/IIIa receptors, of nonpeptide structure, which are active via the parenteral and oral routes.

Substituted 4-phenylthiazole derivatives, process for their preparation

The invention relates to a new method for the secondary prevention of ischemic events comprising administering to a man in need thereof a therapeutically effective amount of a compound selected from clopidogrel and its pharmaceutically acceptable acid addition salts in association with a pharmaceutically acceptable carrier.

Method for the secondary prevention of ischemic events

The present invention relates to a novel process for the elimination of steroid compounds contained in a substance of biological origin by complexing the steroidal compounds by means of a cyclodextrin, in an aqueous medium, under agitation at a temperature between 20.degree. and 80.degree. C. and then separating the complexes so formed.

Process for the elimination of steroid compounds contained in substance

N.alpha.-substituted derivatives of N.alpha.-arylsulphonylaminoacyl p-amidinophenylalaninamides, their preparation, their use as medicaments and intermediates for their synthesis.

Derivatives of the N

In a process for eliminating cholesterol from fatty substances of animal origin used in human diet, the liquefied fatty substances is put into contact with a cyclodextrin, this contact is continued under stirring for 30 minutes to 10 hours at a temperature between the fusion temperature of the fatty substance and 80.degree. C. in such a way as to allow the formation of complexes between the cholesterol and the cyclodextrin, after which the complexes are separated by entrainment in water and separation of the aqueous phase.

Process for eliminating cholesterol contained in a fatty substance of

The present invention is concerned with compounds with the formula: ##STR1## in which: R.sub.1 represents a lower alkyl, a lower hydroxy alkyl or a benzyl group, a phenyl group or a 4-hydroxy phenyl group:

The present invention relates to novel derivatives of alpha-(2-oxo 2,4,5,6,7,7a-hexahydro thieno [3,2-c] 5-pyridyl) phenyl acetic acid corresponding to the following general formula: ##STR1## their addition salts with pharmaceutically-acceptable inorganic or organic acids as well as isomers and their mixtures. The invention also relates to their process of preparation and to medicaments containing these compounds which are of therapeutic use as inhibitors of platelet- and thrombotic-aggregation.

Derivatives of alpha-(2-oxo 2,4,5,6,7,7a-hexahydro

The present invention relates to novel xylan sulfates of average molecular weight comprised between 2000 and 5000 Daltons. The invention also relates to their process of preparation by fractionation and their use in therapeutics as orally active antithrombotic and hypolipaemic agents.

Xylan sulfates of low molecular weight, process for their preparation

Growing community of inventors

Portet/Garonne, France

Jean-Pierre Maffrand